Around 1520% of patients with IBD demonstrate hypermethylation when treated with thiopurines, resulting in preferential metabolism of MP to methylmercaptopurine (MeMP)[54]
they know what theyre doing, and thats what matters most
Any decision to stop treatment must be made collaboratively between the patient, their clinical team, and given the investigational context the trial investigator, weighing the cardiovascular risk against the metabolic benefits of continued therapy
Taking matters into ones own hands by playing with dose sizes is a gamble: It might reduce side effects or costs in the short term, but it could also render the treatment ineffective or introduce new risks, all for unverified benefits
The Microdose GLP-1 Protocol ($129/mo) uses lower initial concentrations to minimize gastric side effects while allowing your body to adapt gradually
And while the metabolic benefits are well known, there are now new reports that GLP-1 agonists may have mood benefits as well. More than metabolism could weight loss drugs boost mood too